Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150040/S023

VISUMAX 800 Femtosecond Laser

Carl Zeiss Meditec, Inc. · Decision date Oct 16, 2025

FDA DECISIONP150040/S023

What did the FDA decide?

FDA records P150040/S023 as a supplement to PMA P150040, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 16, 2025.

FDA approval order statement

adding a new production diagnostic tool for the VISUMAX 800 Femtosecond Laser scan system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 16, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P150040/S023
Regulatory pathway
PMA supplement
Product code
OTL
Decision code
OK30
Decision date
Oct 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Femtosecond laser system for refractive correction.

Product code
OTL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150040/S023 received

    Application receipt date recorded by FDA.

  2. P150040/S023 · FDA decision

    30-Day Notice

  3. P150040/S025 · Related supplement

    Visumax Femtosecond Laser

  4. P150040/S024 · Related supplement

    VISUMAX 800 Femtosecond Laser

Timeline entries are records held by MedtechLedger for P150040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150040

Product / regulatory recordCompanyPathwayDecision dateSource
Carl Zeiss Meditec, Inc.PMA supplementAug 21, 2025FDA
Carl Zeiss Meditec, Inc.PMA supplementDec 18, 2025FDA
Carl Zeiss Meditec, Inc.PMA supplementMay 20, 2026FDA
Carl Zeiss Meditec, Inc.PMA supplementMay 26, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Carl Zeiss Meditec, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5160 Hacienda Dr., Dublin, CA, 94568

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records